Nuclear Nox4-Derived Reactive Oxygen Species in Myelodysplastic Syndromes

Table 1

Clinical, hematologic, and cytogenetic characteristics of MDS patients.

WHO diagnosis	Karyotype	Treatment	Clinical outcome
RARS	Normal		Stable disease
RCMD	del (7q)		Disease progression, death
RCMD	del (20q)	EPO	AML
RAEB1	Normal	5-aza	RAEB2
RAEB1	del (5q)	Idrossiurea (HU)	Stable disease
RAEB1	del (7q)	Idrossiurea (HU)	Stable disease
RAEB2	Tris (8)	5-aza	AML, death
RAEB2	Tris (8)	5-aza	AML, death
RAEB2	Normal	5-aza	AML, death
AML	Normal	5-aza	AML, death